Get the Stockscreener App
72.88
1.69%
1.21
After Hours:
73.31
0.43
+0.59%
Henry Schein Inc stock is traded at $72.88, with a volume of 1.54M.
It is up +1.69% in the last 24 hours and up +12.75% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
See More
Previous Close:
$71.67
Open:
$72.04
24h Volume:
1.54M
Relative Volume:
1.02
Market Cap:
$8.58B
Revenue:
$12.50B
Net Income/Loss:
$314.00M
P/E Ratio:
29.87
EPS:
2.44
Net Cash Flow:
$421.00M
1W Performance:
-3.15%
1M Performance:
+12.75%
6M Performance:
+3.27%
1Y Performance:
-3.10%
1-Day Range:
$72.04
$73.15
1-Week Range:
$71.27
$75.51
52-Week Range:
$60.56
$82.49
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
72.88 | 8.44B | 12.50B | 314.00M | 421.00M | 2.44 |
|
MCK
Mckesson Corporation
|
805.37 | 102.41B | 387.09B | 4.23B | 6.01B | 32.12 |
|
COR
Cencora Inc
|
335.31 | 68.03B | 321.33B | 1.57B | 3.21B | 7.9518 |
|
CAH
Cardinal Health Inc
|
199.71 | 48.74B | 234.31B | 1.61B | 4.45B | 6.6243 |
|
AHG
Akso Health Group Adr
|
1.39 | 790.85M | 2.22M | -5.63M | -1.68M | -0.24 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Henry Schein Expands Partnership with vVARDIS - Dentistry Today
2025 Healthy Outcomes Conference: Henry Schein Canada reducing disability leave claims with wellness program - Benefits Canada.com
Curodont Drill-Free Caries Treatment to Be Distributed by Henry Schein Across U.S. Dental Market - Orthodontic Products
HSIC Stock Benefits From Expanded Partnership With vVARDIS - TradingView
A Closer Look at Henry Schein (HSIC) Valuation Following Recent Share Price Momentum - Yahoo Finance
Henry Schein expands vVARDIS distribution deal for drill-free cavity treatment - Investing.com Nigeria
Henry Schein expands vVARDIS distribution deal for drill-free cavity treatment By Investing.com - Investing.com South Africa
Henry Schein expands exclusive distribution partnership with vVARDIS - TipRanks
Henry Schein, Inc. Expands Partnership with Vvardis - MarketScreener
HSIC Stock Set to Benefit From Henry Schein One's Workflow Launch - Yahoo Finance
Is There Opportunity in Henry Schein After 18% Rally and Digital Dentistry Expansion? - simplywall.st
Henry Schein One to unveil smarter workflows at GNYDM - DrBicuspid.com
Henry Schein’s Sixth Annual ‘Think Pink, Practice Pink’ - Dentistry Today
Henry Schein One unveils natively embedded voice workflow at 2025 Greater New York Dental Meeting - Dental Tribune US
Is Henry Schein Inc. stock a safe investment in uncertain markets2025 Market Overview & Fast Entry High Yield Stock Tips - BỘ NỘI VỤ
HMT Limited Stock Analysis Technical Signals for YEARMACD Trading Signals & You’ve Never Seen Stock Picks Like These - earlytimes.in
Why Henry Schein Inc. stock remains undervaluedJuly 2025 Final Week & Safe Capital Growth Trade Ideas - BỘ NỘI VỤ
Henry Schein (HSIC): Evaluating Valuation After Recent Share Price Rebound - Sahm
Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS - The Manila Times
Henry Schein One Unveils Industry-first Natively Embedded Voice Workflow at 2025 Greater New York Dental Meeting - Business Wire
Peering Into Henry Schein Inc's Recent Short Interest - Benzinga
Henry Schein Is Roaring Back After Its Cyber Attack — Can This Sales Comeback Spark a Major Growth Surge? - Smartkarma
Zimmer Biomet, Cigna, Universal Health Services, Henry Schein, and Sotera Health Company Shares Skyrocket, What You Need To Know - Finviz
Applying sector rotation models to Henry Schein Inc.Sell Signal & Stock Market Timing Techniques - newser.com
Using flow based indicators on Henry Schein Inc.Long Setup & Real-Time Buy Signal Notifications - newser.com
Will Henry Schein Inc. rebound enough to break evenMarket Trend Report & Growth Focused Entry Reports - newser.com
Henry Schein Inc. stock volume spike explained2025 Fundamental Recap & AI Driven Stock Price Forecasts - newser.com
What risks investors should watch in Henry Schein Inc. stockOptions Play & Risk Controlled Stock Pick Alerts - newser.com
Henry Schein at Jefferies London: Strategic Growth and Leadership Transition - Investing.com India
Transcript : Henry Schein, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 02 - MarketScreener
Key metrics from Henry Schein Inc.’s quarterly dataJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
Is Henry Schein Inc. stock ready for breakoutInsider Buying & Reliable Breakout Forecasts - newser.com
VP Siegel Files To Sell 4,176 Of Henry Schein Inc [HSIC] - TradingView
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Do Wall Street Analysts Like Henry Schein Stock? - Yahoo Finance
Will Henry Schein Inc. stock attract more institutional investorsTrade Entry Report & AI Forecasted Entry/Exit Points - newser.com
Chart based exit strategy for Henry Schein Inc.Market Weekly Review & Safe Capital Growth Trade Ideas - newser.com
Can Henry Schein Inc. stock hit analyst price targets2025 Earnings Impact & Verified Swing Trading Watchlists - newser.com
What moving averages say about Henry Schein Inc.Risk Management & Community Consensus Stock Picks - newser.com
Henry Schein (HSIC): Fresh Sales Guidance and Strong Earnings Bring Valuation Back Into Focus - Yahoo Finance
What recovery options are there for Henry Schein Inc.Jobs Report & Verified Momentum Stock Ideas - newser.com
What drives Henry Schein Inc stock priceInstitutional Buying Trends & Capitalize On Fast Trends - earlytimes.in
Tools to assess Henry Schein Inc.’s risk profileJuly 2025 Review & Safe Capital Investment Plans - newser.com
Is Henry Schein Inc. stock dividend yield sustainableJuly 2025 Selloffs & Weekly High Return Stock Forecasts - newser.com
Henry Schein, Inc.'s (NASDAQ:HSIC) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - 富途牛牛
Analyzing drawdowns of Henry Schein Inc. with statistical tools2025 Market Sentiment & Free Community Supported Trade Ideas - newser.com
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.47%
1.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):